A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

Brachytherapy and proton therapy are radiation therapies, while HIFU and TULSA are focal therapies with distinct mechanisms. Medicare typically covers HIFU but not TULSA, with potential future ...

Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...

At a per-patient level, 68 Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while 64 Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 lesions. Dual imaging might help.

HIFU treatment failure is more likely when there is cancer involvement at the prostate base. PSMA PET/CT may improve lesion detection and patient selection for focal therapy. The locations of prostate ...

An implantable microdevice safely delivered multiple drugs directly into prostate cancer lesions, enabling assessment of tumor-specific responses. All 14 patients successfully underwent robot-assisted ...